Corbett Road Capital Management’s Charles River Laboratories CRL Stock Holding History

Corbett Road Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,783	Closed	-$672K	–	100
2021 Q4	$672K	Buy	1,783 +57	+3%	+$22.1K	1.15%	24
2021 Q3	$712K	Sell	1,726 -39	-2%	-$16.2K	1.23%	18
2021 Q2	$653K	Sell	1,765 -290	-14%	-$96.8K	1.15%	20
2021 Q1	$596K	Sell	2,055 -234	-10%	-$65K	0.89%	33
2020 Q4	$572K	Sell	2,289 -114	-5%	-$27.1K	0.52%	53
2020 Q3	$544K	Buy	2,403 +628	+35%	+$130K	0.52%	50
2020 Q2	$309K	Buy	+1,775	New	+$283K	0.3%	82

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Corbett Road Capital Management's CRL Position: Q1 2022 in Review

Corbett Road Capital Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 1,783 shares — an estimated $672K sold.

Corbett Road Capital Management first reported a position in CRL in Q2 2020 and held it in 7 quarters. The position peaked at $712K in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Corbett Road Capital Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Corbett Road Capital Management sold 1,783 Charles River Laboratories shares in Q1 2022, an estimated $672K.
Corbett Road Capital Management first reported a position in Charles River Laboratories in Q2 2020 and held it in 7 quarters.
Corbett Road Capital Management's Charles River Laboratories position peaked at $712K in Q3 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Corbett Road Capital Management's 13F filing for Q1 2022, filed 10 May 2022.